Eli Lilly/$LLY
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Ticker
$LLY
Sector
Primary listing
NYSE
Employees
47,000
Headquarters
Website
Eli Lilly Metrics
BasicAdvanced
$918B
50.16
$20.44
0.39
$5.80
0.59%
Price and volume
Market cap
$918B
Beta
0.39
52-week high
$1,033.62
52-week low
$623.78
Average daily volume
3.7M
Dividend rate
$5.80
Financial strength
Current ratio
1.546
Quick ratio
0.724
Long term debt to equity
171.664
Total debt to equity
178.516
Dividend payout ratio (TTM)
28.28%
Interest coverage (TTM)
26.44%
Profitability
EBITDA (TTM)
28,728.6
Gross margin (TTM)
83.03%
Net profit margin (TTM)
30.99%
Operating margin (TTM)
45.16%
Effective tax rate (TTM)
18.18%
Revenue per employee (TTM)
$1,260,000
Management effectiveness
Return on assets (TTM)
17.60%
Return on equity (TTM)
96.47%
Valuation
Price to earnings (TTM)
50.156
Price to revenue (TTM)
15.5
Price to book
38.6
Price to tangible book (TTM)
80.23
Price to free cash flow (TTM)
130.865
Free cash flow yield (TTM)
0.76%
Free cash flow per share (TTM)
7.835
Dividend yield (TTM)
0.57%
Forward dividend yield
0.59%
Growth
Revenue change (TTM)
45.41%
Earnings per share change (TTM)
121.01%
3-year revenue growth (CAGR)
26.66%
10-year revenue growth (CAGR)
11.67%
3-year earnings per share growth (CAGR)
45.39%
10-year earnings per share growth (CAGR)
24.87%
3-year dividend per share growth (CAGR)
15.24%
10-year dividend per share growth (CAGR)
11.29%
What the Analysts think about Eli Lilly
Analyst ratings (Buy, Hold, Sell) for Eli Lilly stock.
Eli Lilly Financial Performance
Revenues and expenses
Eli Lilly Earnings Performance
Company profitability
Eli Lilly News
AllArticlesVideos
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
CNBC Television21 hours ago
Eli Lilly Strikes Deal With Trump: Why Shares Are Up 10% Since
MarketBeat23 hours ago
Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes
Reuters1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Eli Lilly stock?
Eli Lilly (LLY) has a market cap of $918B as of November 15, 2025.
What is the P/E ratio for Eli Lilly stock?
The price to earnings (P/E) ratio for Eli Lilly (LLY) stock is 50.16 as of November 15, 2025.
Does Eli Lilly stock pay dividends?
Yes, the Eli Lilly (LLY) stock pays dividends to shareholders. As of November 15, 2025, the dividend rate is $5.8 and the yield is 0.59%. Eli Lilly has a payout ratio of 28.28% on a trailing twelve-month basis.
When is the next Eli Lilly dividend payment date?
The next Eli Lilly (LLY) dividend payment is scheduled for December 10, 2025.
What is the beta indicator for Eli Lilly?
Eli Lilly (LLY) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.